BACKGROUND: For this report, the authors estimated the maximum tolerated dose (MTD) and investigated the toxicities of oxaliplatin combined with irinotecan in children with refractory solid tumors. METHODS: Oxaliplatin was administered on Days 1 and 8 in combination with irinotecan on Days 1 through 5 and Days 8 through 12 of a 21-day cycle. An oral cephalosporin was administered daily to ameliorate irinotecan-associated diarrhea. Pharmacokinetic studies of oxaliplatin and uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotyping were performed. RESULTS: Thirteen patients were enrolled. Dose-limiting diarrhea (n = 3), serum lipase elevation (n = 3), serum amylase elevation (n = 2), colitis, abdominal pain, and headache (n = 1 each) occurred at the first dose level (oxaliplatin at a dose of 60 mg/m(2); irinotecan at a dose of 20 mg/m(2)). Only 1 of 7 patients who received reduced doses of both agents (40 mg/m(2)/dose oxaliplatin; 15 mg/m(2)/dose irinotecan) experienced a dose-limiting toxicity (DLT): diarrhea. When the oxaliplatin dose was re-escalated (60 mg/m(2)) with irinotecan at a dose of 15 mg/m(2), 2 of 3 patients had a DLT (1 episode of diarrhea, 1 episode of hypokalemia). Myelosuppression was minimal. One patient had a complete response, and another patient had stable disease for 6 cycles of therapy. The median oxaliplatin area under the concentration versus time curve (AUC(0-->infinity)) was 5.9 microg . hour/mL (range, 1.8-7.6 microg . hour/mL). The frequency of the 6/6, 6/7, and 7/7 UGT1A1 promoter genotypes was 5 of 10, 4 of 10, and 1 of 10, respectively. CONCLUSIONS: The oxaliplatin MTD was 40 mg/m(2) per dose on Days 1 and 8 in combination with irinotecan 15 mg/m(2) per dose on Days 1-5 and Days 8-12. There was some evidence of antitumor activity; however, severe toxicity, both expected (diarrhea) and unexpected (elevation in pancreatic enzymes), was observed.
BACKGROUND: For this report, the authors estimated the maximum tolerated dose (MTD) and investigated the toxicities of oxaliplatin combined with irinotecan in children with refractory solid tumors. METHODS:Oxaliplatin was administered on Days 1 and 8 in combination with irinotecan on Days 1 through 5 and Days 8 through 12 of a 21-day cycle. An oral cephalosporin was administered daily to ameliorate irinotecan-associated diarrhea. Pharmacokinetic studies of oxaliplatin and uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotyping were performed. RESULTS: Thirteen patients were enrolled. Dose-limiting diarrhea (n = 3), serum lipase elevation (n = 3), serum amylase elevation (n = 2), colitis, abdominal pain, and headache (n = 1 each) occurred at the first dose level (oxaliplatin at a dose of 60 mg/m(2); irinotecan at a dose of 20 mg/m(2)). Only 1 of 7 patients who received reduced doses of both agents (40 mg/m(2)/dose oxaliplatin; 15 mg/m(2)/dose irinotecan) experienced a dose-limiting toxicity (DLT): diarrhea. When the oxaliplatin dose was re-escalated (60 mg/m(2)) with irinotecan at a dose of 15 mg/m(2), 2 of 3 patients had a DLT (1 episode of diarrhea, 1 episode of hypokalemia). Myelosuppression was minimal. One patient had a complete response, and another patient had stable disease for 6 cycles of therapy. The median oxaliplatin area under the concentration versus time curve (AUC(0-->infinity)) was 5.9 microg . hour/mL (range, 1.8-7.6 microg . hour/mL). The frequency of the 6/6, 6/7, and 7/7 UGT1A1 promoter genotypes was 5 of 10, 4 of 10, and 1 of 10, respectively. CONCLUSIONS: The oxaliplatin MTD was 40 mg/m(2) per dose on Days 1 and 8 in combination with irinotecan 15 mg/m(2) per dose on Days 1-5 and Days 8-12. There was some evidence of antitumor activity; however, severe toxicity, both expected (diarrhea) and unexpected (elevation in pancreatic enzymes), was observed.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: W Kern; B Beckert; N Lang; J Stemmler; M Beykirch; J Stein; E Goecke; T Waggershauser; J Braess; A Schalhorn; W Hiddemann Journal: Ann Oncol Date: 2001-05 Impact factor: 32.976
Authors: M K Ma; W C Zamboni; K M Radomski; W L Furman; V M Santana; P J Houghton; S K Hanna; A K Smith; C F Stewart Journal: Clin Cancer Res Date: 2000-03 Impact factor: 12.531
Authors: S Blaney; S L Berg; C Pratt; S Weitman; J Sullivan; L Luchtman-Jones; M Bernstein Journal: Clin Cancer Res Date: 2001-01 Impact factor: 12.531
Authors: E Wasserman; C Cuvier; F Lokiec; F Goldwasser; S Kalla; D Méry-Mignard; M Ouldkaci; A Besmaine; G Dupont-André; M Mahjoubi; M Marty; J L Misset; E Cvitkovic Journal: J Clin Oncol Date: 1999-06 Impact factor: 44.544
Authors: W Scheithauer; G V Kornek; M Raderer; J Valencak; G Weinländer; M Hejna; K Haider; W Kwasny; D Depisch Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Uma H Athale; Clinton Stewart; John F Kuttesch; Albert Moghrabi; William Meyer; Charles Pratt; Amar Gajjar; Richard L Heideman Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Y Bécouarn; E Gamelin; B Coudert; S Négrier; J Y Pierga; J L Raoul; J Provençal; O Rixe; C Krisch; C Germa; M Bekradda; D Mignard; M Mousseau Journal: J Clin Oncol Date: 2001-11-15 Impact factor: 44.544
Authors: Margaret E Macy; Tracey Duncan; James Whitlock; Stephen P Hunger; Jessica Boklan; Aru Narendren; Cynthia Herzog; Robert J Arceci; Rochelle Bagatell; Tanya Trippett; Uwe Christians; Katherine Rolla; S Percy Ivy; Lia Gore Journal: Pediatr Blood Cancer Date: 2012-09-28 Impact factor: 3.167
Authors: Lisa M McGregor; Clinton F Stewart; Kristine R Crews; Michael Tagen; Amy Wozniak; Jianrong Wu; M Beth McCarville; Fariba Navid; Victor M Santana; Peter J Houghton; Wayne L Furman; Carlos Rodriguez-Galindo Journal: Pediatr Blood Cancer Date: 2011-04-20 Impact factor: 3.167
Authors: Catherine G Lam; Wayne L Furman; Chong Wang; Sheri L Spunt; Jianrong Wu; Percy Ivy; Victor M Santana; Lisa M McGregor Journal: J Pediatr Hematol Oncol Date: 2015-01 Impact factor: 1.289
Authors: Francisco Bautista; Victoria Fioravantti; Teresa de Rojas; Fernando Carceller; Luis Madero; Alvaro Lassaletta; Lucas Moreno Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452